GT103
GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG3 kappa
Human
GT103 (50 μg/mL; overnight) binds to formalin-fixed, paraffin-embedded human NSCLC tumor tissue sections, with no detectable binding to formalin-fixed, paraffin-embedded normal human lung tissue sections[1].
GT103 (200 μg/mL; 2 h) increases plasma membrane calreticulin expression by approximately 2-fold in NCI-H460 and A549 human lung cancer cells, with no change in total cellular calreticulin levels[1].
GT103 (200 μg/mL; 24 h) significantly increases C3b/iC3b deposition on NCI-H460 and A549 human lung cancer cells via the classical complement pathway, as deposition is reduced in C1q-depleted but not Factor B-depleted serum[1].
GT103 (200 μg/mL; 2 h) significantly increases C1q surface binding to NCI-H460 human lung cancer cells, which is dependent on the antibody's Fc region[1].
GT103 (250 μg/mL; 4 h) significantly enhances macrophage-mediated ADCP of NCI-H460 human lung cancer cells in vitro[1].
GT103 (200 μg/mL; 1-h pre-treatment) significantly increases Syk kinase phosphorylation in human B cells in vitro, in a complement-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human NCI-H460 large cell lung cancer cells; human A549 lung adenocarcinoma cells
-
Concentration:200 μg/mL (in the presence of 10% NHS)
-
Incubation Time:2 h
-
Result:Increased normalized calreticulin intensity to 1.92 relative to no antibody control in H460 cells.
Increased normalized calreticulin intensity to 2.23 relative to no antibody control in A549 cells.
Caused an approximate 2-fold increase in plasma membrane calreticulin compared to IgG control for both cell lines.
Showed no change in total calreticulin expression in whole-cell lysates.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6-8 weeks old, subcutaneous implantation of 2.0 × 105 CMT167 lung tumor cells)[1]
-
Dosage:200 μg/mouse
-
Administration:i.p.; three times weekly; 2 weeks
-
Result:Reduced tumor growth compared to control treatment.
Induced higher calreticulin mean fluorescence intensity (MFI) in CMT167 tumors.
Increased deposition of C3b/iC3b/C3c fragments in CMT167 tumors.
Increased mean levels of C3dg and C3d in CMT167 tumor lysates, approximately 2-fold higher than control tumors.
Upregulated genes related to B-cell MHC class II antigen presentation, antibody production, germinal center function, and mature B-cell survival in intratumoral B cells.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
P08603
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[GT103]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz